Navtemadlin - Kartos Therapeutics
Alternative Names: AMG 232; KRT-232Latest Information Update: 04 Jul 2024
At a glance
- Originator Amgen
- Developer Amgen; GSK; Kartos Therapeutics; National Cancer Institute (USA); Telios Pharmaceuticals; Vanderbilt University Medical Center
- Class Acetic acids; Antineoplastics; Chlorobenzenes; Piperidines; Small molecules; Sulfones
- Mechanism of Action Proto-oncogene protein c-mdm2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Myelofibrosis
- Phase II/III Endometrial cancer
- Phase II Polycythaemia vera; Small cell lung cancer
- Phase I/II Acute myeloid leukaemia; Chronic lymphocytic leukaemia; Chronic myeloid leukaemia; Diffuse large B cell lymphoma; Malignant melanoma; Merkel cell carcinoma
- No development reported Adenoid cystic carcinoma; Glioblastoma; Multiple myeloma; Soft tissue sarcoma; Solid tumours
Most Recent Events
- 03 Jun 2024 Phase-III clinical trials in Myelofibrosis (Combination therapy) in USA (PO) (NCT06479135)
- 22 Mar 2024 Kartos Therapeutics withdraws prior to enrollment a phase I/II trial in Non-small cell lung cancer (Combination therapy, Late-stage disease, Second-line therapy or greater, Metastatic disease) (PO) due to sponsor's decision (NCT05705466)
- 09 Dec 2023 Pharmacodynamics data from a preclinical data in Acute Myeloid Leukemia presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-2023)